Sangamo Therapeutics Inc banner

Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 0.262 USD -2.96% Market Closed
Market Cap: $108.5m

During the last 3 months Sangamo Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 36% over this period (open performance analysis).

The last transaction was made on Sep 26, 2023 by Biogen Inc. , who sold 3m USD worth of SGMO shares.

Last Transactions:
Biogen Inc.
$-3m
Biogen Inc.
$-526.5k
Biogen Inc.
$-2.1m
Markels John
$+25k
Parker H Stewart
$+18k
Biogen Inc.
$-23.5k
Biogen Inc.
$-5.1k
Biogen Inc.
$-694.5k
Biogen Inc.
$-202.5k
Biogen Inc.
$-654.8k
Biogen Inc.
$-444.4k
Biogen Inc.
$-15.9k
Biogen Inc.
$-6.2k
Biogen Inc.
$-248.4k
Loeb Gary
$-157k
Ramelmeier Rolf Andrew
$-41.2k
Ramelmeier Rolf Andrew
$-60.4k
Ramasastry Saira
$-132.7k
Dilly Stephen George
$-210k
Parker H Stewart
$+15.6k
Zakrzewski Joseph S
$+25k
Dilly Stephen George
$-90.3k
Zakrzewski Joseph S
$+28.4k
Zakrzewski Joseph S
$+94.7k
Yi Kathy
$-50k
Yi Kathy
$-60.6k
Yi Kathy
$-50k
Yi Kathy
$-50k
Yi Kathy
$-55.2k
Conner Edward R.
$-61.6k
Yi Kathy
$-57.2k
Conner Edward R.
$-57.4k
View All Transactions

During the last 3 months Sangamo Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 36% over this period (open performance analysis).

The last transaction was made on Sep 26, 2023 by Biogen Inc. , who sold 3m USD worth of SGMO shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Sangamo Therapeutics Inc
Insider Trading Chart

Sangamo Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Sangamo Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Sangamo Therapeutics Inc
Glance View

Market Cap
108.5m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
LOCKED
Unlock

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett